In response to the recent Association of British Pharmaceutical Industry (ABPI) report, which showed a sharp decline (41%) in clinical trials initiated by the UK in the period 2017 to 2021,
Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.
UK biotech Nucleome Therapeutics has been thrust into the spotlight thanks to a £37.5 million ($40 million) first-round financing that will be used to explore so-called 'dark' regions of th
Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clini
